GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
Business Wire•07/10/2026•08:30 ET
0
Key Highlights
- ➤GUARDIAN enrolled 30,000 newborns, demonstrating genomic newborn screening feasibility
- ➤72.3% of approached families enrolled, indicating strong parent participation
- ➤76% of participating newborns represented non-European genetic ancestry
- ➤Eight infants with GUARDIAN-identified Long QT syndrome began beta-blocker therapy
- ➤BRIDGES-NBS will enroll across eight states using 746 genes for 777 treatable conditions
Expert Statements
Linda Genen, Chief Medical Officer at GeneDx
“Genomic newborn screening shows what becomes possible when we move healthcare upstream, identifying risk and acting before a child becomes sick”
Linda Genen, Chief Medical Officer at GeneDx
“These findings demonstrate the potential to bring genomics into screening at scale, across diverse populations and alongside existing public health systems”
Linda Genen, Chief Medical Officer at GeneDx
“This is how we move from reacting to disease to anticipating it, intervening earlier and changing the trajectory of a child’s life.”
GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
New GUARDIAN data demonstrates strong parent participation, consistent sequencing performance across diverse ancestries and actionable insights for newborns and families
Get started
Create a free account to read the full story.